LeMaitre Vascular (NASDAQ:LMAT) Receives Outperform Rating from Barrington Research

Barrington Research reiterated their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research report sent to investors on Wednesday,Benzinga reports. Barrington Research currently has a $120.00 price objective on the medical instruments supplier’s stock.

LMAT has been the topic of a number of other research reports. Roth Mkm reissued a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Citizens Jmp boosted their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Weiss Ratings raised LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 20th. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Finally, Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Up 0.0%

Shares of LeMaitre Vascular stock opened at $91.64 on Wednesday. The business’s 50 day simple moving average is $106.22 and its 200 day simple moving average is $95.74. LeMaitre Vascular has a 52-week low of $79.00 and a 52-week high of $118.01. The firm has a market cap of $2.09 billion, a PE ratio of 33.82, a P/E/G ratio of 2.55 and a beta of 0.54. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. During the same quarter last year, the firm earned $0.48 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, analysts predict that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 1.1%. LeMaitre Vascular’s payout ratio is 36.90%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. The trade was a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Trent G. Kamke sold 2,928 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider directly owned 3,749 shares in the company, valued at $401,143. The trade was a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 54,453 shares of company stock valued at $5,906,174 in the last 90 days. 7.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LMAT. Sound Income Strategies LLC increased its holdings in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 183 shares during the last quarter. Cornerstone Planning Group LLC increased its holdings in shares of LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $32,000. MAI Capital Management acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $38,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.